FMTX Forma Therapeutics Holdings Inc.

Biotech Analyst Ratings

Latest News

1. 06 May 2022 Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

   Clinical programs advancing in rare hematologic diseases and cancers

   May 26 R&D Day to focus on research pipeline strategy and expanded development programs

   Cash balance of $441.3 million positions company with runway through the third quarter of 2024

   Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the first quarter ended March 31, 2022. The company also highlighted recent progress and upcoming milestones for its pipeline programs.

   "The first quarter of 2022 was one of continued progress in enrolling ongoing trials of etavopivat and FT-7051, and also expansion into…

   View Full Article
2. 29 April 2022 Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022

   Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release first quarter 2022 financial results Friday, May 6, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern Daylight Time (EDT) on May 6, 2022 to discuss these financial results and provide a business update.

   Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 1879297. A live webcast of the conference call will be available in the "News & Investors" section of Forma's website at www.formatherapeutics.com…

   View Full Article
3. 01 March 2022 Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

   Clinical stage programs focused on rare hematologic diseases and cancers

   Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III trial enrolling

   Initial FT-7051 Phase I results in mCRPC showed tolerability/safety and signs of pharmacodynamic and clinical activity; escalating dose results expected mid-2022

   Well-capitalized with nearly $500 million in cash providing runway through the third quarter of 2024

   Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results…

   View Full Article
4. 23 February 2022 Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022

   Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2021 financial results Tuesday, March 1, 2022. Forma management will host an investment community conference call at 8 a.m. Eastern Standard Time (EST), on March 1, 2022 to discuss these financial results and provide a business update.

   Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 3322907. A live webcast of the conference call will be available in the "News & Investors" section of Forma's website…

   View Full Article
5. 08 February 2022 Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference

   Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will present at the virtual 11^th Annual SVB Leerink Global Healthcare Conference taking place Feb. 14-18, 2022. Forma will present on Feb. 16, 2022 at 11:20 a.m. Eastern Standard Time (EST).

   A webcast of the conference presentation will be available in the "News & Investors" section of Forma's website at www.FormaTherapeutics.com.

   About Forma Therapeutics

   Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients…

   View Full Article